Discordant somatic and germline VEGF-A genotype in a cancer patient resistant to paclitaxel/bevacizumab with chemosensitive hepatic metastasis

Pharmacogenomics

Volumn 10, Issue 8, 2009, Pages 1225-1229

  Coltelli, Luigi ^a   Allegrini, Giacomo ^b   Orlandi, Paola ^c   Giuntini, Nicola ^a   Alì, Greta ^c   Fioravanti, Anna ^c   Bona, Eleonora ^a   Barletta, Maria Teresa ^a   Fontanini, Gabriella ^c   Del Tacca, Mario ^c   Danesi, Romano ^c   Falcone, Alfredo ^a,c   Bocci, Guido ^c  

^a Azienda USL 6   (Italy)

^b Azienda USL 5 Como   (Italy)

^c UNIVERSITY OF PISA   (Italy)

Author keywords

Bevacizumab; Genotype; Metastatic breast cancer; Paclitaxel VEGF A

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; DOCETAXEL; EPIRUBICIN; ETOPOSIDE; GEMCITABINE; GOSERELIN; NAVELBINE; PACLITAXEL; TAMOXIFEN; VASCULOTROPIN A; ZOLEDRONIC ACID;

ADULT; ARTICLE; BLOOD TOXICITY; BONE METASTASIS; BREAST CANCER; CANCER GRADING; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER STAGING; CASE REPORT; DRUG SENSITIVITY; DRUG WITHDRAWAL; FEMALE; GENE EXPRESSION; GENOTYPE; HUMAN; IMMUNOHISTOCHEMISTRY; INTRADUCTAL CARCINOMA; LIVER METASTASIS; MULTIPLE CYCLE TREATMENT; NEUROTOXICITY; OFF LABEL DRUG USE; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; TREATMENT RESPONSE; TUMOR VASCULARIZATION;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; DISEASE-FREE SURVIVAL; DNA; DNA, NEOPLASM; DRUG RESISTANCE, NEOPLASM; FEMALE; GENOTYPE; HUMANS; HYPERTENSION; LIVER NEOPLASMS; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; PACLITAXEL; POLYMORPHISM, GENETIC; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 70649111383     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.09.55     Document Type: Article

References (11)

1. Pasqualetti G, Danesi R, Del Tacca M, Bocci G: Vascular endothelial growth factor pharmacogenetics: a new perspective for anti-angiogenic therapy. Pharmacogenomics 8(1), 49-66 (2007). ■ First to hypothesize the role of VEGF-A pharmacogenetics in anti-angiogenic therapy. (Pubitemid 46157757)
2. Schneider BP, Wang M, Radovich M et al.: Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. J. Clin. Oncol. 26(28), 4672-4678 (2008). ■ First experimental evidence of a significant relationship between tumor VEGF-A genotypes and overall survival in patients treated with bevacizumab.
3. Schneider BP, Skaar TC, Sledge GW, Badve S, Li L, Flockhart DA: Analysis of angiogenesis genes from paraffin-embedded breast tumor and lymph nodes. Breast Cancer Res. Treat. 96(3), 209-215 (2006).
4. Fontanini G, Faviana P, Lucchi M et al.: A high vascular count and overexpression of vascular endothelial growth factor are associated with unfavourable prognosis in operated small cell lung carcinoma. Br. J. Cancer 86(4), 558-563 (2002). (Pubitemid 34185092)
5. Kerbel RS: Antiangiogenic therapy: a universal chemosensitization strategy for cancer? Science 312(5777), 1171-1175 (2006). ■ Milestone review and perspective on the field of anti-angiogenic therapy.
6. Fontanini G, Vignati S, Boldrini L et al.: Vascular endothelial growth factor is associated with neovascularization and influences progression of non-small cell lung carcinoma. Clin. Cancer Res. 3(6), 861-865 (1997). (Pubitemid 27252933)
7. Yang SX, Steinberg SM, Nguyen D, Wu TD, Modrusan Z, Swain SM: Gene expression profile and angiogenic marker correlates with response to neoadjuvant bevacizumab followed by bevacizumab plus chemotherapy in breast cancer. Clin. Cancer Res. 14(18), 5893-5899 (2008). ■ Very interesting pilot study on possible molecular markers of response to bevacizumab.
8. Yang SX, Swain SM: Reply to the Letter to the Editor from Jubb. Clin. Cancer Res. 15(1), 414 (2009).
9. Hurwitz H, Fehrenbacher L, Novotny W et al.: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 350(23), 2335-2342 (2004). (Pubitemid 38702844)
10. Miller K, Wang M, Gralow J et al.: Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N. Engl. J. Med. 357(26), 2666-2676 (2007).
11. Miller KD, Chap LI, Holmes FA et al.: Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J. Clin. Oncol. 23(4), 792-799 (2005).